Context Therapeutics Acquires Phase 1-Ready T Cell Engager CT-95, Formerly Owned By Link Immunotherapeutics; No Terms Disclosed

CT-95, formerly owned by Link Immunotherapeutics, a mesothelin x CD3 T cell engaging bispecific antibody with first-in-class potential that has received Investigational New Drug clearance from the U.S. Food and Drug Administration. CT-95 is on track for Phase 1 initiation in the first quarter of 2025.

CT-95 is an IND-cleared asset that it plans to rapidly progress into clinical trials. It intends to fund the acquisition of CT-95 and its advancement through the dose escalation portion of a Phase 1 clinical trial with existing cash.